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Abstract 
Caveolae are curved lipid raft regions rich in cholesterol and sphingolipids found abundantly in 
vascular endothelial cells, adipocytes, smooth muscle cells, and fibroblasts. They are multifunctional 
organelles with roles in clathrin-independent endocytosis, cholesterol transport, mechanosensing, 
and signal transduction. Caveolae provide an environment where multiple receptor signalling 
components are sequestered, clustered, and compartmentalised for efficient signal transduction. 
Many of these receptors, including cytokine signal transducer gp130, are mediators of chronic 
inflammation during atherogenesis. Subsequently, disruption of these organelles is associated with a 
broad-range of disease states including cardiovascular disease and cancer. Cavin-1 is an essential 
peripheral component of caveolae that stabilises caveolin-1, the main structural/integral membrane 
protein of caveolae. Caveolin-1 is an essential regulator of endothelial nitric oxide synthase (eNOS)   
and its disruption leads to endothelial dysfunction which initiates a range of cardiovascular and 
pulmonary disorders. While dysfunctional cytokine signalling is also a hallmark of cardiovascular 
disease, knowledge of caveolae-dependent cytokine signalling is lacking as is the role of cavin-1 
independent of caveolae. This review will introduce caveolae, its structural components, the 
caveolins and cavins, their regulation by cAMP, and their potential role in cardiovascular disease. 
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Caveolae 
Initially described in 1953 [1] using electron microscopy, caveolae are 50-100nm cup/omega-shaped 
[2] stable lipid raft regions found abundantly in vascular endothelial cells, adipocytes, smooth 
muscle cells, and fibroblasts. Caveolae account for 50% of the surface area of adipocytes and around 
20% of the surface area of continuous microvascular endothelium [3]. These multifunctional 
organelles have roles in endocytosis, cholesterol homeostasis, mechanosensing, and signal 
transduction, as reviewed by Razani et al [4]. Caveolae provide a cholesterol- and sphingolipid-rich 
environment that sequesters and compartmentalises multiple receptor and non-receptor signalling 
components such as cytokine receptors e.g. gp130 and endothelial nitric oxide synthase (eNOS) [5] 
(Figure 1A). Caveolae formation and function are dependent on the integral membrane proteins 
caveolin-1-3 and the peripheral proteins cavin-1-4. Membrane curvature is critical for the regulation 
of signal transduction, for example, non-caveolae caveolin-1 is unable to inhibit eNOS  [6]. Loss of 
caveolae results in a broad-range of disease states such as lipodystrophy [7], muscular dystrophy [7], 
cardiovascular disease [8], and cancer [9–12], possibly due to the plethora of signalling components 
which it regulates.  
The biogenesis of caveolae has been described elsewhere [13]. In brief, homo-oligomers of 
caveolin-1 and hetero-oligomers of caveolin-1/2 are formed in cholesterol, sphingolipid-rich regions 
within the endoplasmic reticulum (ER) while larger oligomeric complexes are formed within the 
Golgi. Maturation continues following budding, trafficking, and fusing with the plasma membrane, 
the latter of which involves syntaxin-6 [14]. Palmitoylation anchors caveolin oligomers at the plasma 
membrane. Cavins co-localise with mature caveolins only at the plasma membrane, where they 
regulate membrane curvature, depth of caveolae, and endocytosis [13]. Cavins do not directly 
interact with caveolins but potentially requires several adaptor proteins such as filamin [15], 
syndapin (pacsin)II [16], Eps15 homology domain-containing 2 [17],  and dynamin [16]. Once formed, 
caveolae exist as stable structures that are disrupted by endocytic events or disease states. 
Cholesterol is essential for caveolae biogenesis and as such cholesterol-depleting agents such as 
methyl-β-cyclodextrin (MCD), filipin, and statins (nystatin, lovastatin) prevent the formation of 
caveolae.  
 
Caveolae, cAMP, and inflammatory signalling 
Caveolae sequester multiple receptor signalling complexes such as the gp130 receptor [18], a 
mediator of inflammation during atherogenesis [19]. The IL6-stimulated gp130 receptor is negatively 
regulated by the cAMP-inducible suppressor of cytokine signalling (SOCS) 3 [20]. SOCS3 is present at 
low basal levels but is rapidly elevated in response to activation of adenylyl cyclase (AC).  SOCS3 
inhibits IL6 signalling by directly binding gp130 and constitutively attached Janus kinase (JAKs) and 
by forming an elongin-cullin-SOCS (ECS) E3 ubiquitin ligase and thus targeting substrates for K48-
polyubiquitination and proteasomal degradation. Cyclic-AMP-modulating signalling components also 
localise to caveolae such as AC isoforms 3, 5, and 6, PDE3B, and GPCRs [21] while loss of caveolae 
results in the redistribution AC but with increased isoproterenol-stimulated cAMP production [22]. 
Thus compartmentalising modulators of cAMP and cAMP-regulated signalling components suggests 
a link between caveolae and cAMP-mediated regulation of pro-inflammatory responses.  
Caveolae are themselves cAMP-regulated signalling organelles, for example, caveolin-1 is 
down-regulated in response to cAMP  in rat cardiac myoblasts (H9C2 cells) and smooth muscle cells 
(RASMC) [22]. In addition, caveolin-1 mRNA has been reported to be up-regulated in response to 
several cytokines including TNFα [23]. Caveolae have been demonstrated to be essential for IL6 
signalling in multiple myeloma cells positive for caveolin-1 [18]. Cholesterol depletion by MCD as 
well as inhibition of caveolin-1 phosphorylation was enough to block IL6 signalling as well as 
signalling via the Akt-1 pathway implicating both membrane curvature and caveolin-1-dependent 
regulation. Furthermore, signal transducers and activators of transcription (STATs), the downstream 
effectors of IL6 signalling, have been detected in DRM isolated from human hepatoma Hep3B cells 
along with gp130 and caveolin-1 [24]. STAT activation was found to be reduced following MCD 
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treatment indicating the importance of caveolae in IL6 mediated events [24]. Interestingly, caveolin-
1 has been shown to have SOCS functionality via its ability to inhibit prolactin-induced STAT5 
signalling. All caveolin family members share sequence similarities with SOCS1/3 within the kinase 
inhibitory region (KIR) while all JAKs contain a caveolin-binding domain (CBD) [23]. Thus, caveolins 
might directly bind JAKs via a conserved KIR [25]. As such, caveolae/caveolins might be significant 
regulators of cytokine signalling.   
SOCS3 is induced by several stimuli including cytokines (IL6), chemo-attractants (IL8), and 
also by bacterial components (LPS, CpG DNA) via activation of toll-like receptors (TLRs). Interestingly, 
TLR3-dependent polyinosinic-polycytidylic acid-induced gene expression of SOCS3 is down-regulated 
in mandarin fish (Siniperca chuatsi) following expression of the scaffold domain of a caveolin-1 
homologue [26]. As such, structural components of caveolae might be involved in the regulation of 
cytokine signalling at several levels. 
In summary, these data suggest and intimate link between caveolae, cAMP, cytokine 
signalling, and the inflammatory response highlighting their potential as therapeutic drug targets. 
 
Caveolae: the building blocks 
Caveolins 
Caveolins are a family of three integral membrane proteins (caveolin-1-3) which serve as the main 
structural components of caveolae. While forming hairpin-shaped proteins, they do not penetrate 
the outer leaflet of the plasma membrane and have both N- and C-terminal domains facing the 
cytoplasm. Caveolin-1/2 are co-expressed in most cell types with highest levels found in endothelial 
cells and adipocytes, while caveolin-3 is limited to cardiac, skeletal, and vascular smooth muscle cells 
[27]. The role of caveolin-2 is unclear since it is not essential for caveolae formation, while in 
contrast, caveolin-3 is essential for caveolae formation in muscle. This is supported by the finding 
that caveolae are not present in vascular endothelial cells or adipocytes from caveolin-1 knockout 
(KO) mice but are still present in skeletal muscle [28]. Caveolin-1 directly binds cholesterol which is 
essential for caveolae formation. In fact, overexpressing caveolin-1 dramatically increases (70%) 
cholesterol levels within plasma membrane [29].  
Caveolins have been highlighted as a drug target for cardiovascular disease and has been 
recently reviewed [30]. Caveolin-1 is critical in regulating inflammatory signalling  via sequestration 
and inhibition of eNOS via the caveolin-1 scaffold domain (amino acids 82-101) [31]. As such, loss of 
caveolin-1 leads to enhanced AKT and ERK1/2 signalling resulting in several cardiovascular 
phenotypes [32–34]. For example, while caveolin-1 KO mice models are viable, they develop 
pulmonary hypertension and cardiac hypertrophy [35]. These phenotypes can be rescued by either 
expression of a peptide containing the scaffold domain or genetic deletion of eNOS [36], suggesting 
a functional link between the two.  
In contrast to its protective effects, caveolin-1/caveolae are thought to regulate the 
transcytosis of LDL in blood vessels resulting in the accumulation of pro-atherogenic lipids in the sub-
endothelial space, which is important for lesion formation [37]. As such, loss of caveolin-1 has been 
suggested to be protective against atherosclerosis [37]. 
 
The cavin family 
The cavin family has four members with predicted molecular weights ranging from 31 to 47kDa, 
cavin-1 (PTRF, polymerase I and transcript release factor), cavin-2 (SDPR, serum deprivation 
response protein), cavin-3 (SRBC, sdr-related gene product that binds to-c-kinase), and cavin-4 
(MURC, muscle restricted coiled-coiled protein) where cavin-1 is the most highly expressed and most 
intensively studied. Cavin-1-3 are expressed ubiquitously at differing levels in a cell/tissue-specific 
manner but are found most abundantly in endothelial cells, adipocytes, fibroblasts, and epithelial 
cells [38,39] while cavin-4 is restricted to striated muscle. A 3D structure of members of the cavin 
family is lacking, common structural features include leucine-zipper motifs, PEST (Pro-Glu-Ser-Thr-
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rich) domains, and phospho-regulatory sites [3,38]. Cavins aggregate into large 60S oligomeric 
complexes (the cavin complex)[38] and can do so in the absence of caveolins [13], although the 
significance of this is not known. Each cavin family member also binds phosphatidylserine (PS) which 
is enriched within the inner leaflet of the plasma membrane. By making several weak interactions 
with PS, the cavin complex can strengthen its association with caveolae. This also opens up the 
possibility that altering the lipid environment might regulate the association of the cavin complex 
with the plasma membrane.   
Functionally, while cavin-4 seems to substitute for cavin-1 within muscle tissue each 
member provides non-redundant functionality. Cavin-1 stabilises caveolae by anchoring caveolin-1 
to the cytoskeleton via a C-terminal region [40]. Initially, only cavin-1 was thought essential for 
caveolae formation, however recent data has shown cavin-2 to be essential in lung and adipose 
tissue[3]. Furthermore, cavin-2 modulates the size of the cavin complex and regulates caveolae 
depth. Thus the degree of cavin-2 expression might create heterogeneous caveolae complexes and 
functionality in a tissue-specific manner [3].  
While functional studies into the significance of cavin-2-4 are on-going, this review will focus 
on cavin-1, the most intensively studied of the cavin family. 
  
Cavin-1/PTRF 
Cavin-1 (Figure 1B) was first identified in 1998 as PTRF involved in the dissociation of paused 
ternary transcription complexes [41]. Cavin-1 has since been revealed as an essential component of 
caveolae [42]. Supporting this dual role, Lui et al showed that only 50% of cellular cavin-1 co-
localises with caveolin-1 in detergent-resistant rafts isolated from adipocytes via gradient 
centrifugation [40]. Within caveolae, cavin-1 regulates membrane curvature by stabilising caveolin-1, 
the main structural component of caveolae [40]. Expression of cavin-1 and caveolin-1 are tightly 
linked such that overexpression of cavin-1 results in a concomitant increase in caveolin-1 while its 
loss results in a global loss of caveolae due to increased lateral motion and lysosomal degradation or 
mislocalisation of caveolin-1/2 [43]. Furthermore, genetic deletion of cavin-1 in mice leads to 
impaired caveolae formation and loss of stability of all three caveolins [43]. Interestingly, cavin-1 like 
caveolin-1 is stably expressed but are also induced by stress conditions including starvation [44], 
catecholamines [44], and oxidative stress, leading to increased numbers of caveolae [45].  
While stabilising caveolin-1, cavin-1 appears to not directly interact with caveolin-1 but is 
instead linked by one of many yet to be identified adaptor protein(s). Thus cavin-1 co-
immunoprecipitates with caveolin-1 in Triton-X100 (1%) solubilised cell lysates (intact lipid-raft) but 
not in octylglucoside treated cells (solubilised lipid-raft) which is indicative of an indirect interaction. 
Current data suggest that cavin-1 links caveolae to the microtubule network via a C-terminal region 
since a ∆C74 cavin-1 mutant localises to microtubule bundles [40]. Furthermore, disruption of actin 
cytoskeleton with latrunculin B or the microtubule network with nocodazole disrupts cavin-1 protein 
levels but not caveolin-1 suggesting rapid turnover of non-caveolae cavin-1 [40].  
Cavin-1 has a predicted mass of 43kDa but is frequently detected at 50-60kDa following SDS-
PAGE. Such a shift is characteristic of multiple post-translational modifications, indeed, cavin-1 has 
been detected in phosphorylated [42], SUMOylated, and ubiquitinated (Williams, J.J.L & Palmer T.M, 
unpublished) forms. In adipose tissue, cavin-1 acts as an adaptor protein for hormone sensitive 
lipase (HSL) which regulates the release of triglycerides during periods of fasting. Following 
starvation or treatment and subsequent elevation in intracellular cAMP, cavin-1 is phosphorylated in 
a PKA-dependent fashion [44] at multiple sites, with S42, T304, and S368 being essential for HSL 
activation. Upon re-feeding or treatment with insulin, cavin-1 is tyrosine phosphorylated at Y14, 
Y158, Y310, and Y318 resulting in translocation of both proteins to the cytoplasm while excess cAMP 
is removed by PDE3B thus preventing further lipolysis by HSL [44]. Thus, Cavin-1 might function as a 
general phospho-regulated adaptor protein [44,46] however the full range of cavin-1 binding 
partners is unknown.  
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Cavin-1 and disease 
Cavin-1 KO mice have a lipodystrophic phenotype i.e. high circulating triglyceride levels, reduced 
adipose tissue mass, glucose intolerance, and hyperinsulinaemia [40]. This phenotype might stem 
from the impaired triglyceride uptake and storage by adipocytes due to the lack of caveolae[43]. This 
phenotype closely matches that of humans with cavin-1 mutations with the addition of 
cardiovascular and pulmonary disorders found in caveolin-1 KO mice mentioned previously [7,8,47]. 
Expression of cavin-1 is either lost or C-terminally truncated resulting in loss of caveolae in 
fibroblasts and muscle tissue [7,8,47]. This effect was also demonstrated in adipocytes using a 
synthetically generated ∆C74 cavin-1 mutant [40]. 
Expression of cavin-1 and caveolin-1 are closely linked however this fine balance is lost 
following diet-induced atherosclerosis. Uyy et al have demonstrated that DRMs isolated from lung 
endothelial cells of APOE-/- mice fed on a high-fat diet were modified so that caveolin-1 and pAKT1 
was up-regulated while cavin-1 levels were reduced [48]. As a result, loss of caveolae and 
dysfunctional caveolae-dependent signalling e.g. eNOS would be expected. The authors point out 
that this could account for pulmonary disorders which are associated with cardiovascular disease 
[48]. 
 
Perspectives  
It is evident that caveolae have a role in cardiovascular disease but while loss of caveolae is 
detrimental, the individual roles of cavins and caveolins are unclear. As such, pathologies resulting 
from loss of caveolae due to loss of either protein family members might only partially overlap since 
the caveolae-independent roles for each protein is not yet fully appreciated. Thus delineating the 
roles of the individual caveolae structural proteins will be essential for therapeutic intervention. 
Furthermore, while cavin-1 is a substrate for multiple post-translational modifications such as 
phosphorylation, ubiquitination, and SUMOylation, their importance for caveolae stability and signal 
transduction is underexplored. Also limiting is the lack of structural information that will aid the 
understanding of protein interaction and regulation.   
While caveolae and caveolins-1 have been demonstrated to be essential for IL6 signalling, 
the role of cavin-1 has not been assessed. It is intriguing that, all caveolin family members share 
sequence similarities with SOCS1/3 within the KIR while all JAKs contain caveolin-binding domains 
[23]. However, the significance of these findings with regard to cytokine signalling has yet to be fully 
addressed. Doing so might unveil further avenues of therapeutic intervention.  
An exciting possibility is that by varying expression of caveolae structural proteins, a 
heterogeneous group of caveolae organelles can be produced [3]. Each member might then a 
different function via selection of resident signalling components.  Mechanistically, disruption of the 
cavin complex by mechanical stress and subsequent loss of caveolin-1-dependent inhibition of eNOS 
is thought to be central to caveolae mechnosensing [49]. It might be possible that there other 
mechanisms by which this might occur either pathological or other. 
 Given the multiple roles of cavin-1, if effectively targeted, it might be possible to treat a 
variety of disorders such as cardiomyopathy and pulmonary disorders, atherosclerosis, and 
lipodystrophy.  
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Figure 1: Caveolae and cavin-1 
A. Caveolae are curved lipid-raft regions rich in cholesterol and sphingolipids which act as a platform 
for efficient signal transduction. AC, adenylyl cyclase; eNOS, endothelial nitric oxide synthase; GPCR, 
G protein-coupled receptor; glycoprotein 130. B.  A 3D structure of cavin-1 is lacking, however, 
predicted structural features include three leucine-rich regions (LLR), three PEST (Pro-Glu-Ser-Thr-
rich) domains, and two nuclear localisation signals (NLS).  
  
8 
 
1  Palade, G. E. (1953) Fine structure of blood capillaries. J. Appl. Phys. 24, 1424. 
2  Schlörmann, W., Steiniger, F., Richter, W., Kaufmann, R., Hause, G., Lemke, C. and 
Westermann, M. (2010) The shape of caveolae is omega-like after glutaraldehyde fixation 
and cup-like after cryofixation. Histochem. Cell Biol. 133, 223–8. 
3  Hansen, C. G., Shvets, E., Howard, G., Riento, K. and Nichols, B. J. (2013) Deletion of cavin 
genes reveals tissue-specific mechanisms for morphogenesis of endothelial caveolae. Nat. 
Commun., Nature Publishing Group 4, 1831. 
4  Razani, B., Woodman, S. E. and Lisanti, M. P. (2002) Caveolae: from cell biology to animal 
physiology. Pharmacol. Rev. 54, 431–67. 
5  Patel, H. H., Murray, F. and Insel, P. a. (2008) Caveolae as organizers of pharmacologically 
relevant signal transduction molecules. Annu. Rev. Pharmacol. Toxicol. 48, 359–91. 
6  Sowa, G., Pypaert, M. and Sessa, W. C. (2001) Distinction between signaling mechanisms in 
lipid rafts vs. caveolae. Proc. Natl. Acad. Sci. U. S. A. 98, 14072–7. 
7  Shastry, S., Delgado, M. R., Dirik, E., Turkmen, M., Agarwal, A. K. and Garg, A. (2010) 
Congenital generalized lipodystrophy, type 4 (CGL4) associated with myopathy due to novel 
PTRF mutations. Am. J. Med. Genet. A 152A, 2245–53. 
8  Rajab, A., Straub, V., McCann, L. J., Seelow, D., Varon, R., Barresi, R., Schulze, A., Lucke, B., 
Lützkendorf, S., Karbasiyan, M., et al. (2010) Fatal cardiac arrhythmia and long-QT syndrome 
in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to 
PTRF-CAVIN mutations. PLoS Genet. 6, e1000874. 
9  Bai, L., Deng, X., Li, J., Wang, M., Li, Q., An, W., a, D. and Cong, Y.-S. (2011) Regulation of 
cellular senescence by the essential caveolar component PTRF/Cavin-1. Cell Res., Nature 
Publishing Group 21, 1088–101. 
10  Gámez-Pozo, A., Sánchez-Navarro, I., Calvo, E., Agulló-Ortuño, M. T., López-Vacas, R., Díaz, E., 
Camafeita, E., Nistal, M., Madero, R., Espinosa, E., et al. (2012) PTRF/cavin-1 and MIF proteins 
are identified as non-small cell lung cancer biomarkers by label-free proteomics. PLoS One 7, 
e33752. 
11  Chamberlain, L. H., Burgoyne, R. D. and Gould, G. W. (2001) SNARE proteins are highly 
enriched in lipid rafts in PC12 cells: implications for the spatial control of exocytosis. Proc. 
Natl. Acad. Sci. U. S. A. 98, 5619–24. 
12  Hill, M. M., Daud, N. H., Aung, C. S., Loo, D., Martin, S., Murphy, S., Black, D. M., Barry, R., 
Simpson, F., Liu, L., et al. (2012) Co-regulation of cell polarization and migration by caveolar 
proteins PTRF/Cavin-1 and caveolin-1. PLoS One 7, e43041. 
13  Hayer, A., Stoeber, M., Bissig, C. and Helenius, A. (2010) Biogenesis of caveolae: stepwise 
assembly of large caveolin and cavin complexes. Traffic 11, 361–82. 
14  Choudhury, A., Marks, D. L., Proctor, K. M., Gould, G. W. and Pagano, R. E. (2006) Regulation 
of caveolar endocytosis by syntaxin 6-dependent delivery of membrane components to the 
cell surface. Nat. Cell Biol. 8, 317–28. 
9 
 
15  Stahlhut, M. and van Deurs, B. (2000) Identification of filamin as a novel ligand for caveolin-1: 
evidence for the organization of caveolin-1-associated membrane domains by the actin 
cytoskeleton. Mol. Biol. Cell 11, 325–37. 
16  Koch, D., Westermann, M., Kessels, M. M. and Qualmann, B. (2012) Ultrastructural freeze-
fracture immunolabeling identifies plasma membrane-localized syndapin II as a crucial factor 
in shaping caveolae. Histochem. Cell Biol. 138, 215–30. 
17  Morén, B., Shah, C., Howes, M. T., Schieber, N. L., McMahon, H. T., Parton, R. G., Daumke, O. 
and Lundmark, R. (2012) EHD2 regulates caveolar dynamics via ATP-driven targeting and 
oligomerization. Mol. Biol. Cell 23, 1316–29. 
18  Podar, K., Tai, Y.-T., Cole, C. E., Hideshima, T., Sattler, M., Hamblin, A., Mitsiades, N., 
Schlossman, R. L., Davies, F. E., Morgan, G. J., et al. (2003) Essential role of caveolae in 
interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple 
myeloma cells. J. Biol. Chem. 278, 5794–801. 
19  Ortiz-Muñoz, G., Martin-Ventura, J. L., Hernandez-Vargas, P., Mallavia, B., Lopez-Parra, V., 
Lopez-Franco, O., Muñoz-Garcia, B., Fernandez-Vizarra, P., Ortega, L., Egido, J., et al. (2009) 
Suppressors of cytokine signaling modulate JAK/STAT-mediated cell responses during 
atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 29, 525–31. 
20  Sands, W. A., Woolson, H. D., Milne, G. R., Rutherford, C. and Palmer, T. M. (2006) Exchange 
protein activated by cyclic AMP (Epac)-mediated induction of suppressor of cytokine signaling 
3 (SOCS-3) in vascular endothelial cells. Mol. Cell. Biol. 26, 6333–46. 
21  Willoughby, D. and Cooper, D. M. F. (2007) Organization and Ca2+ Regulation of Adenylyl 
Cyclases in cAMP Microdomains. Physiol Rev. 87, 965–1010. 
22  Yamamoto.M, Okumura.S, Oka.N,Schwencke.C, I. . (1999) Downregulation of caveolin 
expression by cAMP signal. Life Sci. 64, 1349–1357. 
23  Jasmin, J.-F., Mercier, I., Sotgia, F. and Lisanti, M. P. (2006) SOCS proteins and caveolin-1 as 
negative regulators of endocrine signaling. Trends Endocrinol. Metab. 17, 150–8. 
24  Sehgal, P. B., Guo, G. G., Shah, M., Kumar, V. and Patel, K. (2002) Cytokine signaling: STATS in 
plasma membrane rafts. J. Biol. Chem. 277, 12067–74. 
25  Park, D. S., Lee, H., Frank, P. G., Razani, B., Nguyen, A. V, Parlow, A. F., Russell, R. G., Hulit, J., 
Pestell, R. G. and Lisanti, M. P. (2002) Caveolin-1-deficient Mice Show Accelerated Mammary 
Gland Development During Pregnancy , Premature Lactation , and Hyperactivation of the Jak-
2 / STAT5a Signaling Cascade 13, 3416–3430. 
26  Guo, C.-J., Yang, X.-B., Wu, Y.-Y., Yang, L.-S., Mi, S., Liu, Z.-Y., Jia, K.-T., Huang, Y.-X., Weng, S.-
P., Yu, X.-Q., et al. (2011) Involvement of caveolin-1 in the Jak-Stat signaling pathway and 
infectious spleen and kidney necrosis virus infection in mandarin fish (Siniperca chuatsi). Mol. 
Immunol., Elsevier Ltd 48, 992–1000. 
27  Tang Z-L, Scherer PE, Okamoto T, Song K, Chu C, Kohtz DS, Nishimoto I, Lodish HF, and L. M. 
(1996) Molecular cloning of caveolin-3, a novel member of the caveolin gene family 
expressed predominantly in muscle. J. Biol. Chem. 271, 2255– 2261. 
10 
 
28  Le Lay, S. and Kurzchalia, T. V. (2005) Getting rid of caveolins: phenotypes of caveolin-
deficient animals. Biochim. Biophys. Acta 1746, 322–33. 
29  Liu, L. and Pilch, P. F. (2008) A critical role of cavin (polymerase I and transcript release factor) 
in caveolae formation and organization. J. Biol. Chem. 283, 4314–22. 
30  Sellers, S. L., Trane, A. E. and Bernatchez, P. N. (2012) Caveolin as a potential drug target for 
cardiovascular protection. Front. Physiol. 3, 280. 
31  Garcia-Cardena, G. (1997) Dissecting the Interaction between Nitric Oxide Synthase (NOS) 
and Caveolin. J. Biol. Chem. 272, 25437–25440. 
32  Engelman, J. a, Chu, C., Lin, a, Jo, H., Ikezu, T., Okamoto, T., Kohtz, D. S. and Lisanti, M. P. 
(1998) Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in 
vivo. A role for the caveolin-scaffolding domain. FEBS Lett. 428, 205–11. 
33  Jasmin, J.-F., Mercier, I., Sotgia, F. and Lisanti, M. P. (2006) SOCS proteins and caveolin-1 as 
negative regulators of endocrine signaling. Trends Endocrinol. Metab. 17, 150–8. 
34  Sedding, D. G., Hermsen, J., Seay, U., Eickelberg, O., Kummer, W., Schwencke, C., Strasser, R. 
H., Tillmanns, H. and Braun-Dullaeus, R. C. (2005) Caveolin-1 facilitates mechanosensitive 
protein kinase B (Akt) signaling in vitro and in vivo. Circ. Res. 96, 635–42. 
35  Sowa, G. (2012) Caveolae, caveolins, cavins, and endothelial cell function: new insights. Front. 
Physiol. 2, 120. 
36  Bernatchez, P., Sharma, A., Bauer, P. M., Marin, E. and Sessa, W. C. (2011) A noninhibitory 
mutant of the caveolin-1 scaffolding domain enhances eNOS-derived NO synthesis and 
vasodilation in mice 121. 
37  Frank, P. G., Pavlides, S., Cheung, M. W., Daumer, K. and Lisanti, M. P. (2008) Role of caveolin-
1 in the regulation of lipoprotein metabolism 19107, 242–248. 
38  Bastiani, M., Liu, L., Hill, M. M., Jedrychowski, M. P., Nixon, S. J., Lo, H. P., Abankwa, D., 
Luetterforst, R., Fernandez-Rojo, M., Breen, M. R., et al. (2009) MURC/Cavin-4 and cavin 
family members form tissue-specific caveolar complexes. J. Cell Biol. 185, 1259–73. 
39  Dávalos, A., Fernández-Hernando, C., Sowa, G., Derakhshan, B., Lin, M. I., Lee, J. Y., Zhao, H., 
Luo, R., Colangelo, C. and Sessa, W. C. (2010) Quantitative proteomics of caveolin-1-regulated 
proteins: characterization of polymerase i and transcript release factor/CAVIN-1 IN 
endothelial cells. Mol. Cell. Proteomics 9, 2109–24. 
40  Liu, L. and Pilch, P. F. (2008) A critical role of cavin (polymerase I and transcript release factor) 
in caveolae formation and organization. J. Biol. Chem. 283, 4314–22. 
41  Jansa, P., Mason, S. W., Hoffmann-Rohrer, U. and Grummt, I. (1998) Cloning and functional 
characterization of PTRF, a novel protein which induces dissociation of paused ternary 
transcription complexes. EMBO J. 17, 2855–64. 
11 
 
42  Aboulaich, N., Vainonen, J. P., Strålfors, P. and Vener, A. V. (2004) Vectorial proteomics reveal 
targeting, phosphorylation and specific fragmentation of polymerase I and transcript release 
factor (PTRF) at the surface of caveolae in human adipocytes. Biochem. J. 383, 237–48. 
43  Liu, L., Brown, D., McKee, M., Lebrasseur, N. K., Yang, D., Albrecht, K. H., Ravid, K. and Pilch, P. 
F. (2008) Deletion of Cavin/PTRF causes global loss of caveolae, dyslipidemia, and glucose 
intolerance. Cell Metab. 8, 310–7. 
44  Aboulaich, N., Chui, P. C., Asara, J. M., Flier, J. S. and Maratos-Flier, E. (2011) Polymerase I and 
transcript release factor regulates lipolysis via a phosphorylation-dependent mechanism. 
Diabetes 60, 757–65. 
45  Volonte, D. and Galbiati, F. (2011) Polymerase I and transcript release factor (PTRF)/cavin-1 is 
a novel regulator of stress-induced premature senescence. J. Biol. Chem. 286, 28657–61. 
46  Zhu, H., Lin, P., De, G., Choi, K., Takeshima, H., Weisleder, N. and Ma, J. (2011) Polymerase 
transcriptase release factor (PTRF) anchors MG53 protein to cell injury site for initiation of 
membrane repair. J. Biol. Chem. 286, 12820–4. 
47  Hayashi, Y. K., Matsuda, C., Ogawa, M., Goto, K., Tominaga, K., Mitsuhashi, S., Park, Y., 
Nonaka, I., Hino-fukuyo, N. and Haginoya, K. (2009) Human PTRF mutations cause secondary 
deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy 119. 
48  Uyy, E., Ivan, L., Boteanu, R. M., Suica, V. I. and Antohe, F. (2013) High-fat diet alters protein 
composition of detergent-resistant membrane microdomains. Cell Tissue Res. 354, 771–81. 
49  Parton, R. G. and del Pozo, M. a. (2013) Caveolae as plasma membrane sensors, protectors 
and organizers. Nat. Rev. Mol. Cell Biol., Nature Publishing Group 14, 98–112.  
 
